Context for Organon stock
Organon (OGN) has been on investors’ radar after recent share price weakness, with the stock closing at US$6.03 and showing negative total returns over the month, past 3 months and year.
See our latest analysis for Organon.
The recent share price decline, including a 19.17% 30 day share price return and a 60.44% 1 year total shareholder return, points to changing momentum as investors reassess Organon’s risk profile and future prospects.
If Organon’s recent weakness has you thinking about diversification, this could be a good moment to see what else is moving through 35 healthcare AI stocks.
With Organon trading at US$6.03, a value score of 5, an intrinsic discount near 90% and a market cap of about US$1.63b, the key question is clear: is this real upside or is the market already pricing in future growth?
Most Popular Narrative: 33% Undervalued
With Organon’s fair value narrative at $9.00 against a last close of $6.03, the story centers on whether earnings and margins can catch up with this gap.
The company's continued debt reduction and strong free cash flow generation enhance financial flexibility, enabling further pipeline investments and M&A opportunities, both of which can accelerate long-term earnings growth and mitigate risks from patent cliffs or single-segment concentration.
Curious what kind of revenue trajectory, margin lift and future P/E multiple are built into that $9.00 fair value for Organon? The narrative leans on a specific mix of slow top line assumptions, much faster profit growth and a compressed earnings multiple that sits well below many peers.
Result: Fair Value of $9.00 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, there are still clear pressure points, including exposure to off patent brands and U.S. policy uncertainty around funded contraception, that could derail the current fair value story.
Find out about the key risks to this Organon narrative.
Next Steps
The mix of concerns and optimism around Organon is clear, so this is a moment to move quickly and test the story against your own expectations using 3 key rewards and 3 important warning signs
Looking for more investment ideas?
Do not stop your research at a single stock. Broaden your watchlist with focused idea lists that can surface opportunities you might otherwise overlook.
- Target potential income pillars by scanning for companies in the 13 dividend fortresses that could complement or strengthen your portfolio’s cash flow.
- Hunt for mispriced quality by reviewing the 52 high quality undervalued stocks and see which businesses the data flags as trading below their implied worth.
- Prioritise resilience by checking the 68 resilient stocks with low risk scores so you are not missing companies with steadier risk profiles than your current holdings.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com